FMP
Eledon Pharmaceuticals, Inc.
ELDN
NASDAQ
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
4.36 USD
0.14 (3.21%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. David-Alexandre C. Gros M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://eledon.comexchange
NASDAQ
Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2...
CIK
0001404281
ISIN
US28617K1016
CUSIP
28617K101
Address
19900 MacArthur Boulevard
Phone
949 238 8090
Country
US
Employee
20
IPO Date
Sep 17, 2014
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ELDN Financial Summary
CIK
0001404281
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
28617K101
ISIN
US28617K1016
Country
US
Price
4.36
Beta
0.77
Volume Avg.
491.88k
Market Cap
260.46M
Shares
-
52-Week
1.43-5.54
DCF
0.17
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
5.97
P/B
-
Website
https://eledon.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ELDN News
It looks like there's no news available.
